Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4054 Predictive factors of persistent thrombocytopenia after 177Lu-DOTATATE in patients with neuroendocrine tumors

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective and well tolerated treatment for advanced Neuroendocrine Tumors (NET). However, some Persistent Thrombocytopenia (PT) are described and may compromise further therapies and outcome.

Conference:

Presenting Author:

Authors: Oziel-Taieb S, Ferrara R, Charrier N, Maniry J, Reichert T,

Keywords: Neuroendocrine Tumor, PRRT, LuDOTATATE, Thrombocytopenia, Bone metastases, spleen,

#3459 Short-term tolerability and dose toxicity evaluation of 177Lu-DOTATATE for advanced neuroendocrine tumors (NET)

Introduction: 177Lu-DOTATATE has become a valuable treatment option in the management of advanced NET. However, PRRT treatment is usually limited by kidney toxicity, where the radiopharmaceutical is reabsorbed and retained, or bone marrow by evident hematological toxicity or in the liver.

Conference:

Presenting Author: Bonilla Plaza J

Authors: Bonilla Plaza J, Martinez Lorca A, Navarro Martinez T, Azpeitia Hernandez P, Alonso-Gordoa T,

Keywords: PRRT, 177Lu, Toxicity,

#411 Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy with 177Lu-DOTATATE (177Lu-PRRT) has shown activity against advanced well-differentiated pancreatic neuroendocrine tumors (P-NET) in previous phase I/II studies.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O,

Keywords: neuroendocrine, peptide receptor radionuclide therapy,